Limited Coverage Drugs – Tiotropium inhalation solution

Generic Name

Strength 2.5 mcg


Solution for oral inhalation via inhaler

Special Authority Criteria

Approval Period

Diagnosis of COPD where spirometry measures are:

  • FEV1 as a percentage of predicted value (less than or equal to 65%)


  • Ratio of actual FEV1 / FVC (less than 0.7)


  • Inadequate response after 3 month trial of either:
    • Ipratropium at a dose of 12 puffs daily


  • Ipratropium and salbutamol combination inhaler (Combivent Respimat) at a dose of 6 puffs daily1.


  1. 12 puffs of ipratropium via metered dose inhaler is equivalent to 6 puffs of ipratropium via Combivent Respimat inhaler.









Practitioner Exemptions

  • Practitioners in the following specialty are not required to submit a Special Authority request form for coverage: Respirology.

Special Notes

  • In remote areas, where spirometry access is limited, spirometry measurements are to be provided within 6 months.
  • Patients who meet the Special Authority criteria for aclidinium/glycopyrronium/tiotropium/umeclidinium will automatically receive coverage of Spiriva Respimat.

Special Authority Request Form(s)